| Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor EB Gomez, K Ebata, HS Randeria, MS Rosendahl, EP Cedervall, ... Blood, The Journal of the American Society of Hematology 142 (1), 62-72, 2023 | 65 | 2023 |
| Unique pharmacodynamic properties conferred by differential binding to BTK, pirtobrutinib vs covalent inhibitors JA Ballard, K Ebata, HS Randeria, G Tinline, T Lee, LM Hanson, ... Cancer Research 83 (7_Supplement), 2780-2780, 2023 | 1 | 2023 |
